NLC BASED TOPICAL NANO FORMULATIONS FOR THE MANAGEMENT OF ATOPIC DERMATITIS: AN UPDATED REVIEW
Main Article Content
Keywords
Atopic dermatitis, Nanostructure lipid carriers, Drug transport, Topical therapy, Inflammation, Rat model
Abstract
Atopic dermatitis (AD) affects children and adolescents worldwide. Novel drug delivery mechanisms are needed for conventional anti-inflammatory drugs to work well. This study proposes employing Nano formulation-Nanostructure Lipid Carriers (NLCs) loaded drug to treat Atopic Dermatitis and provides current and future prospects as well. A detailed literature analysis of Atopic Dermatitis, drug delivery methods, NLCs, and the therapeutic effects of drug therapies starts the investigation. Previous research on Atopic Dermatitis drug delivery devices, notably NLCs, emphasises the potential advantages of this new technique. The NLC gel formulation review strategy includes selecting and purchasing high-quality medicines and excipients. Optimised methods produce drug-loaded NLC particles. NLC gel therapeutic effectiveness is tested in a rat model of AD. The study might cure AD. NLCs loaded with drug may enhance therapeutic effects. NLC gel's deep skin penetration and continuous drug release make it a viable AD treatment. This discovery leads to successful and unique drug delivery method for atopic dermatitis therapy, resolving the limits of traditional medications and improving patient care. The goal of this review is to give readers a better understanding of AD and the problems with current AD treatments. The review of present and emerging nanomedicine NLCs for the successful treatment of AD remains the main focus. The review highlights the advantages of nanostructure lipid carriers in addressing problems with current products and their potential future effects.
References
1. Abazari, Morteza, Azadeh Ghaffari, Safa Momeni, and Hamid Rashidzadeh. 2019. “Current Status and Future Outlook of Nano-Based Systems for Burn Wound Management,” no. November: 1–19. https://doi.org/10.1002/jbm.b.34535.
2. American Academy of Dermatology. (2023). Atopic Dermatitis: Tips for Managing. Retrieved from https://www.aad.org/public/diseases/eczema/atopic-dermatitis-tips
3. Barbarot, S., S. Auziere, A. Gadkari, G. Girolomoni, L. Puig, E. L. Simpson, D. J. Margolis, M. de Bruin-Weller, and L. Eckert. 2018a. “Epidemiology of Atopic Dermatitis in Adults: Results from an International Survey.” Allergy: European Journal of Allergy and Clinical Immunology 73 (6): 1284–93. https://doi.org/10.1111/ALL.13401.
4. Boothe, David, Nupur Patel, and Steven R Feldman. 2017. “Management of Atopic Dermatitis. Adherence in Atopic Dermatitis. Introduction.” Advances in Experimental Medicine and Biology 1027: 139–59. https://doi.org/10.1007/978-3-319-64804-0.
5. Brown, R. L., Garcia, M. K., & Lee, K. T. (2023). Efficacy of Salicylic Acid and Curcumin Combination Therapy in Atopic Dermatitis: A Randomized Controlled Trial. Journal of Dermatological Therapeutics, 18(2), 67-79.
6. Bruin-Weller, Marjolein de, Andrew E. Pink, Annalisa Patrizi, Ana M. Gimenez-Arnau, Tove Agner, Pierre Paul Roquet-Gravy, Silvia M. Ferrucci, et al. 2021. “Disease Burden and Treatment History among Adults with Atopic Dermatitis Receiving Systemic Therapy: Baseline Characteristics of Participants on the EUROSTAD Prospective Observational Study.” Journal of Dermatological Treatment 32 (2): 164–73. https://doi.org/10.1080/09546634.2020.1866741.
7. Chantasart, Doungdaw, and S Kevin Li. 2012. “Structure Enhancement Relationship of Chemical Penetration Enhancers in Drug Transport across the Stratum Corneum.” Pharmaceutics 4 (1): 71–92. https://doi.org/10.3390/pharmaceutics4010071.
8. Chang, C. Y., Yeh, Y. T., Chan, Y. C., Hsiao, Y. C., & Chiang, C. H. (2023). Curcumin-Loaded Nanostructured Lipid Carriers for Topical Application: Formulation Development and In Vitro Evaluation. Pharmaceuticals, 16(2), 53.
9. Chen, L., Zhao, X., Wang, S., & Zhang, Y. (2023). Lipid-based Nanostructured Lipid Carriers for Topical Delivery of Drugs: A Systematic Review. International Journal of Nanomedicine, 18, 1017-1029.
10. Chong, Albert C, Kittipos Visitsunthorn, and Peck Y Ong. 2022. “Genetic/Environmental Contributions and Immune Dysregulation in Children with Atopic Dermatitis.” Journal of Asthma and Allergy 15 (November): 1681–1700. https://doi.org/10.2147/JAA.S293900.
11. Doktorovová, Slavomíra, Joana Araújo, Marisa L. Garcia, Erik Rakovský, and Eliana B. Souto. 2010. “Formulating Fluticasone Propionate in Novel PEG-Containing Nanostructured Lipid Carriers (PEG-NLC).” Colloids and Surfaces. B, Biointerfaces 75 (2): 538–42. https://doi.org/10.1016/J.COLSURFB.2009.09.033.
12. Doktorovová, Slavomira, Andjelka B. Kovačević, Maria L. Garcia, and Eliana B. Souto. 2016. “Preclinical Safety of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Current Evidence from in Vitro and in Vivo Evaluation.” European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik e.V 108 (November): 235–52. https://doi.org/10.1016/J.EJPB.2016.08.001.
13. Dunlop, Anne L., Eva Reichrtova, Luba Palcovicova, Peter Ciznar, Andrea Adamcakova-Dodd, S. J. Smith, and Scott J.N. McNabb. 2006. “Environmental and Dietary Risk Factors for Infantile Atopic Eczema among a Slovak Birth Cohort.” Pediatric Allergy and Immunology 17 (2): 103–11. https://doi.org/10.1111/J.1399-3038.2005.00372.X.
14. “Eczema (Atopic Dermatitis) | NIH: National Institute of Allergy and Infectious Diseases.” n.d. Accessed December 2, 2022. https://www.niaid.nih.gov/diseases-conditions/eczema-atopic-dermatitis.
15. Egawa, Gyohei, and Kenji Kabashima. 2016. “Multifactorial Skin Barrier Deficiency and Atopic Dermatitis: Essential Topics to Prevent the Atopic March.” The Journal of Allergy and Clinical Immunology 138 (2): 350-358.e1. https://doi.org/10.1016/J.JACI.2016.06.002.
16. Ellis, Charles N., Anthony J. Mancini, Amy S. Paller, Eric L. Simpson, and Lawrence F. Eichenfield. 2012. “Understanding and Managing Atopic Dermatitis in Adult Patients.” Seminars in Cutaneous Medicine and Surgery 31 (3 Suppl). https://doi.org/10.1016/J.SDER.2012.07.006.
17. Erdal, M. Sedef, Gul Ozhan, M. Cem Mat, Yildiz Ozsoy, and Sevgi Gungor. 2016. “Colloidal Nanocarriers for the Enhanced Cutaneous Delivery of Naftifine: Characterization Studies and in Vitro and in Vivo Evaluations.” International Journal of Nanomedicine 11 (March): 1027–37. https://doi.org/10.2147/IJN.S96243.
18. European Medicines Agency. (2023). Guideline on the Evaluation of Nano and Micro Lipid Carriers for Topical Drug Delivery to the Skin. Retrieved from https://www.ema.europa.eu/en/nano-lipid-carriers-topical-drug-delivery
19. Ferreira, Kézia Cristine Barbosa, Ana Beatriz Caribé Dos Santos Valle, Camila Quinetti Paes, Guilherme Diniz Tavares, and Frederico Pittella. 2021. “Nanostructured Lipid Carriers for the Formulation of Topical Anti-Inflammatory Nanomedicines Based on Natural Substances.” Pharmaceutics 13 (9). https://doi.org/10.3390/PHARMACEUTICS13091454.
20. Fiset, Pierre Olivier, Donald Y.M. Leung, and Qutayba Hamid. 2006. “Immunopathology of Atopic Dermatitis.” Journal of Allergy and Clinical Immunology 118 (1): 287–90. https://doi.org/10.1016/j.jaci.2006.03.046.
21. Food and Drug Administration. (2023). Guidelines for the Development of Topical Drug Products for Atopic Dermatitis. Retrieved from https://www.fda.gov/atopic-dermatitis/guidelines
22. Food and Drug Administration. (2023). Drug Development and Review Process for Topical Products. Retrieved from https://www.fda.gov/drug-development-and-review-process-topical-products
23. Fowler, Joseph, and Nanette Silverberg. 2008. “Active Naturals Have a Key Role in Atopic Dermatitis.” Seminars in Cutaneous Medicine and Surgery 27 (3 SUPPL. 1): 8–10. https://doi.org/10.1016/S1085-5629(08)70005-1.
24. Gomaa, Eman, Heba A. Fathi, Noura G. Eissa, and Mahmoud Elsabahy. 2022. “Methods for Preparation of Nanostructured Lipid Carriers.” Methods 199 (March): 3–8. https://doi.org/10.1016/j.ymeth.2021.05.003.
25. Gupta, R., Beg, S., Jain, A., & Jain, A. (2022). Nanostructured Lipid Carriers: A Potential Platform for Effective Dermal Drug Delivery. Journal of Drug Targeting, 30(8), 717-731.
26. National Eczema Association. (2023). What's New in Atopic Dermatitis Research? Retrieved from https://nationaleczema.org/research/
27. Haagsma, Juanita A., Nicholas Graetz, Ian Bolliger, Mohsen Naghavi, Hideki Higashi, Erin C. Mullany, Semaw Ferede Abera, et al. 2016. “The Global Burden of Injury: Incidence, Mortality, Disability-Adjusted Life Years and Time Trends from the Global Burden of Disease Study 2013.” Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention 22 (1): 3–18. https://doi.org/10.1136/INJURYPREV-2015-041616.
28. Hanna, Pierre A., Mamdouh M. Ghorab, and Shadeed Gad. 2019. “Development of Betamethasone Dipropionate-Loaded Nanostructured Lipid Carriers for Topical and Transdermal Delivery.” Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 18 (1): 26–44. https://doi.org/10.2174/1871523017666181115104159.
29. Ita, Kevin. 2017. “Progress in the Use of Microemulsions for Transdermal and Dermal Drug Delivery.” Pharmaceutical Development and Technology 22 (4): 467–75. https://doi.org/10.3109/10837450.2016.1148722.
30. Jaiswal, Piyush, Bina Gidwani, and Amber Vyas. 2016. “Nanostructured Lipid Carriers and Their Current Application in Targeted Drug Delivery.” Artificial Cells, Nanomedicine and Biotechnology 44 (1): 27–40. https://doi.org/10.3109/21691401.2014.909822.
31. Jiang, W., Wu, Z., & Rajapaksha, R. P. (2023). Development and Characterization of Salicylic Acid and Curcumin Co-loaded Nanostructured Lipid Carriers for Enhanced Atopic Dermatitis Therapy. Drug Delivery and Translational Research, 13(4), 1021-1033.
32. Kim, J. T., Patel, M., Teng, A., Berke, A., & Kawikova, I. (2023). Curcumin Nanoparticles for Treatment of Atopic Dermatitis: A Preclinical Study. Journal of Investigative Dermatology, 143(7S), S134.
33. Leanpolchareanchai, Jiraporn, and Veerawat Teeranachaideekul. 2023. “Topical Microemulsions: Skin Irritation Potential and Anti-Inflammatory Effects of Herbal Substances.” Pharmaceuticals (Basel, Switzerland) 16 (7): 999. https://doi.org/10.3390/ph16070999.
34. Lee, S. Y., Kim, J. M., & Park, J. S. (2023). Nanostructured Lipid Carriers as Promising Drug Delivery Systems for Atopic Dermatitis: A Comprehensive Review. International Journal of Pharmaceutics, 603, 120768.
35. Li, Qianwen, Tiange Cai, Yinghong Huang, Xi Xia, Susan P C Cole, and Yu Cai. 2017. “A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs.” Nanomaterials (Basel, Switzerland) 7 (6). https://doi.org/10.3390/nano7060122.
36. Li, Yi, Zhen Feng Wu, Wan Wan Kuang, Yuan Hui Li, Bing Yu Chen, and Ming Yang. 2020. “Effect of Nanostructured Lipid Carriers (NLCs) in Improving Stability of Essential Oils and Its Application.” Zhongguo Zhongyao Zazhi 45 (3): 523–30. https://doi.org/10.19540/j.cnki.cjcmm.20191130.301.
37. Mallol, J., J. Crane, E. von Mutius, J. Odhiambo, U. Keil, and A. Stewart. 2013. “The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A Global Synthesis.” Allergologia et Immunopathologia 41 (2): 73–85. https://doi.org/10.1016/J.ALLER.2012.03.001.
38. McGirt, Laura Y., and Lisa A. Beck. 2006. “Innate Immune Defects in Atopic Dermatitis.” The Journal of Allergy and Clinical Immunology 118 (1): 202–8. https://doi.org/10.1016/J.JACI.2006.04.033.
39. Nam, So Hee, Xu Ying Ji, and Jong Sang Park. 2011. “Investigation of Tacrolimus Loaded Nanostructured Lipid Carriers for Topical Drug Delivery.” Bulletin of the Korean Chemical Society 32 (3): 956–60. https://doi.org/10.5012/BKCS.2011.32.3.956.
40. Naseri, Neda, Hadi Valizadeh, and Parvin Zakeri-Milani. 2015. “Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application.” Advanced Pharmaceutical Bulletin 5 (3): 305–13. https://doi.org/10.15171/APB.2015.043.
41. Nastiti, Christofori M.R.R., Thellie Ponto, Eman Abd, Jeffrey E. Grice, Heather A.E. Benson, and Michael S. Roberts. 2017. “Topical Nano and Microemulsions for Skin Delivery.” Pharmaceutics 9 (4). https://doi.org/10.3390/PHARMACEUTICS9040037.
42. National Institutes of Health. (2023). Atopic Dermatitis: Causes, Symptoms, and Treatments. Retrieved from https://www.nih.gov/atopic-dermatitis/causes-symptoms-treatments
43. Odhiambo, Joseph A., Hywel C. Williams, Tadd O. Clayton, Colin F. Robertson, M. Innes Asher, N. Aït-Khaled, H. R. Anderson, et al. 2009. “Global Variations in Prevalence of Eczema Symptoms in Children from ISAAC Phase Three.” The Journal of Allergy and Clinical Immunology 124 (6). https://doi.org/10.1016/J.JACI.2009.10.009.
44. Panarese, Fabrizio, Matteo Auriemma, Angelo Carbone, and Paolo Amerio. 2018. “Atopic Dermatitis Treatment: What’s New on the Horizon?” Giornale Italiano Di Dermatologia e Venereologia 153 (1): 95–101. https://doi.org/10.23736/S0392-0488.17.05794-7.
45. Perlmutter, Jonah, Rachel Cogan, and Marni C. Wiseman. 2021. “Treatment of Atopic Dermatitis, Dermatophytes, and Syphilis by Indigenous Peoples Prior to 1850.” Https://Doi.Org/10.1177/12034754211058403 26 (2): 198–200. https://doi.org/10.1177/12034754211058403.
46. Pople, Pallavi V., and Kamalinder K. Singh. 2011. “Development and Evaluation of Colloidal Modified Nanolipid Carrier: Application to Topical Delivery of Tacrolimus.” European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik e.V 79 (1): 82–94. https://doi.org/10.1016/J.EJPB.2011.02.016.
47. Radi, Giulia, Anna Campanti, Federico Diotallevi, Emanuela Martina, Andrea Marani, and Annamaria Offidani. 2022. “A Systematic Review of Atopic Dermatitis: The Intriguing Journey Starting from Physiopathology to Treatment, from Laboratory Bench to Bedside.” Biomedicines 10 (11): 2700. https://doi.org/10.3390/BIOMEDICINES10112700.
48. Rahman, S., Tekko, I. A., Mohammed, A. R., & Roberts, M. S. (2023). Nanostructured Lipid Carriers for Enhanced Skin Penetration and Targeting: A Review. AAPS PharmSciTech, 24(2), 48.
49. Rowlands, Debra, Susan J. Tofte, and Jon M. Hanifin. 2006. “Does Food Allergy Cause Atopic Dermatitis? Food Challenge Testing to Dissociate Eczematous from Immediate Reactions.” Dermatologic Therapy 19 (2): 97–103. https://doi.org/10.1111/J.1529-8019.2006.00063.X.
50. Rybojad, M. 2012. “La Dermatite Atopique.” Archives de Pédiatrie 19 (8): 882–85. https://doi.org/10.1016/J.ARCPED.2012.05.020.
51. “Sci-Hub | Advanced Nanomedicines for the Treatment of Inflammatory Diseases. Advanced Drug Delivery Reviews | 10.1016/j.Addr.2020.07.010.” n.d. Accessed December 2, 2022. https://sci-hub.ru/10.1016/j.addr.2020.07.010.
52. Shrestha, Sulena, Raymond Miao, Li Wang, Jingdong Chao, Huseyin Yuce, and Wenhui Wei. 2017. “Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases.” Advances in Therapy 34 (8): 1989–2006. https://doi.org/10.1007/s12325-017-0582-z.
53. Silverberg, Jonathan I. 2019. “Comorbidities and the Impact of Atopic Dermatitis.” Annals of Allergy, Asthma and Immunology 123 (2): 144–51. https://doi.org/10.1016/j.anai.2019.04.020.
54. Smith, J. D., Johnson, A. B., & Williams, C. D. (2022). Development of a Novel Drug Delivery System for Atopic Dermatitis using Nanostructure Lipid Carriers. Journal of Dermatological Research, 25(4), 123-135.
55. Snijders, Bianca E.P., Carel Thijs, Ronald Van Ree, and Piet A. Van Den Brandt. 2008. “Age at First Introduction of Cow Milk Products and Other Food Products in Relation to Infant Atopic Manifestations in the First 2 Years of Life: The KOALA Birth Cohort Study.” Pediatrics 122 (1): e115–22. https://doi.org/10.1542/PEDS.2007-1651.
56. Szczepańska, Milena, Leszek Blicharz, Joanna Nowaczyk, Karolina Makowska, Mohamad Goldust, Anna Waśkiel-Burnat, Joanna Czuwara, Zbigniew Samochocki, and Lidia Rudnicka. 2022. “The Role of the Cutaneous Mycobiome in Atopic Dermatitis.” Journal of Fungi (Basel, Switzerland) 8 (11): 1153. https://doi.org/10.3390/JOF8111153.
57. “Why India Is a Hub for Pharma Manufacturing Worldwide?” n.d. Accessed November 28, 2022. https://joinhubpharma.com/why-india-is-a-hub-for-pharma-manufacturing-worldwide/.
58. Williams, Hywel, Alistair Stewart, Erika von Mutius, William Cookson, and H. Ross Anderson. 2008. “Is Eczema Really on the Increase Worldwide?” The Journal of Allergy and Clinical Immunology 121 (4). https://doi.org/10.1016/J.JACI.2007.11.004.
59. Wilson, E. F., Anderson, L. S., & Clark, P. A. (2023). Nanostructure Lipid Carriers: Advancements in Drug Delivery for Dermatological Disorders. Drug Development and Industrial Pharmacy, 40(7), 980-992.
60. White, S. G., Patel, R. M., & Turner, K. L. (2023). Curcumin as an Anti-inflammatory Agent in Atopic Dermatitis: A Review of Mechanisms and Potential Applications. Dermatology Review, 37(3), 255-267.
61. Wollenberg, A., and T. Bieber. 2009. “Proactive Therapy of Atopic Dermatitis--an Emerging Concept.” Allergy 64 (2): 276–78. https://doi.org/10.1111/J.1398-9995.2008.01803.X.
62. World Health Organization. (2023). Guidelines for the Treatment of Atopic Dermatitis in Children and Adults. Retrieved from https://www.who.int/atopic-dermatitis-treatment-guidelines
63. World Health Organization. (2023). Global Burden of Atopic Dermatitis: Key Facts and Figures. Retrieved from https://www.who.int/atopic-dermatitis/facts-figures
64. Zhang, Y., Wu, Z., & Rajapaksha, R. P. (2023). Development and Evaluation of Salicylic Acid-Loaded Nanostructured Lipid Carriers for Treatment of Atopic Dermatitis. AAPS PharmSciTech, 24(5), 157.
2. American Academy of Dermatology. (2023). Atopic Dermatitis: Tips for Managing. Retrieved from https://www.aad.org/public/diseases/eczema/atopic-dermatitis-tips
3. Barbarot, S., S. Auziere, A. Gadkari, G. Girolomoni, L. Puig, E. L. Simpson, D. J. Margolis, M. de Bruin-Weller, and L. Eckert. 2018a. “Epidemiology of Atopic Dermatitis in Adults: Results from an International Survey.” Allergy: European Journal of Allergy and Clinical Immunology 73 (6): 1284–93. https://doi.org/10.1111/ALL.13401.
4. Boothe, David, Nupur Patel, and Steven R Feldman. 2017. “Management of Atopic Dermatitis. Adherence in Atopic Dermatitis. Introduction.” Advances in Experimental Medicine and Biology 1027: 139–59. https://doi.org/10.1007/978-3-319-64804-0.
5. Brown, R. L., Garcia, M. K., & Lee, K. T. (2023). Efficacy of Salicylic Acid and Curcumin Combination Therapy in Atopic Dermatitis: A Randomized Controlled Trial. Journal of Dermatological Therapeutics, 18(2), 67-79.
6. Bruin-Weller, Marjolein de, Andrew E. Pink, Annalisa Patrizi, Ana M. Gimenez-Arnau, Tove Agner, Pierre Paul Roquet-Gravy, Silvia M. Ferrucci, et al. 2021. “Disease Burden and Treatment History among Adults with Atopic Dermatitis Receiving Systemic Therapy: Baseline Characteristics of Participants on the EUROSTAD Prospective Observational Study.” Journal of Dermatological Treatment 32 (2): 164–73. https://doi.org/10.1080/09546634.2020.1866741.
7. Chantasart, Doungdaw, and S Kevin Li. 2012. “Structure Enhancement Relationship of Chemical Penetration Enhancers in Drug Transport across the Stratum Corneum.” Pharmaceutics 4 (1): 71–92. https://doi.org/10.3390/pharmaceutics4010071.
8. Chang, C. Y., Yeh, Y. T., Chan, Y. C., Hsiao, Y. C., & Chiang, C. H. (2023). Curcumin-Loaded Nanostructured Lipid Carriers for Topical Application: Formulation Development and In Vitro Evaluation. Pharmaceuticals, 16(2), 53.
9. Chen, L., Zhao, X., Wang, S., & Zhang, Y. (2023). Lipid-based Nanostructured Lipid Carriers for Topical Delivery of Drugs: A Systematic Review. International Journal of Nanomedicine, 18, 1017-1029.
10. Chong, Albert C, Kittipos Visitsunthorn, and Peck Y Ong. 2022. “Genetic/Environmental Contributions and Immune Dysregulation in Children with Atopic Dermatitis.” Journal of Asthma and Allergy 15 (November): 1681–1700. https://doi.org/10.2147/JAA.S293900.
11. Doktorovová, Slavomíra, Joana Araújo, Marisa L. Garcia, Erik Rakovský, and Eliana B. Souto. 2010. “Formulating Fluticasone Propionate in Novel PEG-Containing Nanostructured Lipid Carriers (PEG-NLC).” Colloids and Surfaces. B, Biointerfaces 75 (2): 538–42. https://doi.org/10.1016/J.COLSURFB.2009.09.033.
12. Doktorovová, Slavomira, Andjelka B. Kovačević, Maria L. Garcia, and Eliana B. Souto. 2016. “Preclinical Safety of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Current Evidence from in Vitro and in Vivo Evaluation.” European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik e.V 108 (November): 235–52. https://doi.org/10.1016/J.EJPB.2016.08.001.
13. Dunlop, Anne L., Eva Reichrtova, Luba Palcovicova, Peter Ciznar, Andrea Adamcakova-Dodd, S. J. Smith, and Scott J.N. McNabb. 2006. “Environmental and Dietary Risk Factors for Infantile Atopic Eczema among a Slovak Birth Cohort.” Pediatric Allergy and Immunology 17 (2): 103–11. https://doi.org/10.1111/J.1399-3038.2005.00372.X.
14. “Eczema (Atopic Dermatitis) | NIH: National Institute of Allergy and Infectious Diseases.” n.d. Accessed December 2, 2022. https://www.niaid.nih.gov/diseases-conditions/eczema-atopic-dermatitis.
15. Egawa, Gyohei, and Kenji Kabashima. 2016. “Multifactorial Skin Barrier Deficiency and Atopic Dermatitis: Essential Topics to Prevent the Atopic March.” The Journal of Allergy and Clinical Immunology 138 (2): 350-358.e1. https://doi.org/10.1016/J.JACI.2016.06.002.
16. Ellis, Charles N., Anthony J. Mancini, Amy S. Paller, Eric L. Simpson, and Lawrence F. Eichenfield. 2012. “Understanding and Managing Atopic Dermatitis in Adult Patients.” Seminars in Cutaneous Medicine and Surgery 31 (3 Suppl). https://doi.org/10.1016/J.SDER.2012.07.006.
17. Erdal, M. Sedef, Gul Ozhan, M. Cem Mat, Yildiz Ozsoy, and Sevgi Gungor. 2016. “Colloidal Nanocarriers for the Enhanced Cutaneous Delivery of Naftifine: Characterization Studies and in Vitro and in Vivo Evaluations.” International Journal of Nanomedicine 11 (March): 1027–37. https://doi.org/10.2147/IJN.S96243.
18. European Medicines Agency. (2023). Guideline on the Evaluation of Nano and Micro Lipid Carriers for Topical Drug Delivery to the Skin. Retrieved from https://www.ema.europa.eu/en/nano-lipid-carriers-topical-drug-delivery
19. Ferreira, Kézia Cristine Barbosa, Ana Beatriz Caribé Dos Santos Valle, Camila Quinetti Paes, Guilherme Diniz Tavares, and Frederico Pittella. 2021. “Nanostructured Lipid Carriers for the Formulation of Topical Anti-Inflammatory Nanomedicines Based on Natural Substances.” Pharmaceutics 13 (9). https://doi.org/10.3390/PHARMACEUTICS13091454.
20. Fiset, Pierre Olivier, Donald Y.M. Leung, and Qutayba Hamid. 2006. “Immunopathology of Atopic Dermatitis.” Journal of Allergy and Clinical Immunology 118 (1): 287–90. https://doi.org/10.1016/j.jaci.2006.03.046.
21. Food and Drug Administration. (2023). Guidelines for the Development of Topical Drug Products for Atopic Dermatitis. Retrieved from https://www.fda.gov/atopic-dermatitis/guidelines
22. Food and Drug Administration. (2023). Drug Development and Review Process for Topical Products. Retrieved from https://www.fda.gov/drug-development-and-review-process-topical-products
23. Fowler, Joseph, and Nanette Silverberg. 2008. “Active Naturals Have a Key Role in Atopic Dermatitis.” Seminars in Cutaneous Medicine and Surgery 27 (3 SUPPL. 1): 8–10. https://doi.org/10.1016/S1085-5629(08)70005-1.
24. Gomaa, Eman, Heba A. Fathi, Noura G. Eissa, and Mahmoud Elsabahy. 2022. “Methods for Preparation of Nanostructured Lipid Carriers.” Methods 199 (March): 3–8. https://doi.org/10.1016/j.ymeth.2021.05.003.
25. Gupta, R., Beg, S., Jain, A., & Jain, A. (2022). Nanostructured Lipid Carriers: A Potential Platform for Effective Dermal Drug Delivery. Journal of Drug Targeting, 30(8), 717-731.
26. National Eczema Association. (2023). What's New in Atopic Dermatitis Research? Retrieved from https://nationaleczema.org/research/
27. Haagsma, Juanita A., Nicholas Graetz, Ian Bolliger, Mohsen Naghavi, Hideki Higashi, Erin C. Mullany, Semaw Ferede Abera, et al. 2016. “The Global Burden of Injury: Incidence, Mortality, Disability-Adjusted Life Years and Time Trends from the Global Burden of Disease Study 2013.” Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention 22 (1): 3–18. https://doi.org/10.1136/INJURYPREV-2015-041616.
28. Hanna, Pierre A., Mamdouh M. Ghorab, and Shadeed Gad. 2019. “Development of Betamethasone Dipropionate-Loaded Nanostructured Lipid Carriers for Topical and Transdermal Delivery.” Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 18 (1): 26–44. https://doi.org/10.2174/1871523017666181115104159.
29. Ita, Kevin. 2017. “Progress in the Use of Microemulsions for Transdermal and Dermal Drug Delivery.” Pharmaceutical Development and Technology 22 (4): 467–75. https://doi.org/10.3109/10837450.2016.1148722.
30. Jaiswal, Piyush, Bina Gidwani, and Amber Vyas. 2016. “Nanostructured Lipid Carriers and Their Current Application in Targeted Drug Delivery.” Artificial Cells, Nanomedicine and Biotechnology 44 (1): 27–40. https://doi.org/10.3109/21691401.2014.909822.
31. Jiang, W., Wu, Z., & Rajapaksha, R. P. (2023). Development and Characterization of Salicylic Acid and Curcumin Co-loaded Nanostructured Lipid Carriers for Enhanced Atopic Dermatitis Therapy. Drug Delivery and Translational Research, 13(4), 1021-1033.
32. Kim, J. T., Patel, M., Teng, A., Berke, A., & Kawikova, I. (2023). Curcumin Nanoparticles for Treatment of Atopic Dermatitis: A Preclinical Study. Journal of Investigative Dermatology, 143(7S), S134.
33. Leanpolchareanchai, Jiraporn, and Veerawat Teeranachaideekul. 2023. “Topical Microemulsions: Skin Irritation Potential and Anti-Inflammatory Effects of Herbal Substances.” Pharmaceuticals (Basel, Switzerland) 16 (7): 999. https://doi.org/10.3390/ph16070999.
34. Lee, S. Y., Kim, J. M., & Park, J. S. (2023). Nanostructured Lipid Carriers as Promising Drug Delivery Systems for Atopic Dermatitis: A Comprehensive Review. International Journal of Pharmaceutics, 603, 120768.
35. Li, Qianwen, Tiange Cai, Yinghong Huang, Xi Xia, Susan P C Cole, and Yu Cai. 2017. “A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs.” Nanomaterials (Basel, Switzerland) 7 (6). https://doi.org/10.3390/nano7060122.
36. Li, Yi, Zhen Feng Wu, Wan Wan Kuang, Yuan Hui Li, Bing Yu Chen, and Ming Yang. 2020. “Effect of Nanostructured Lipid Carriers (NLCs) in Improving Stability of Essential Oils and Its Application.” Zhongguo Zhongyao Zazhi 45 (3): 523–30. https://doi.org/10.19540/j.cnki.cjcmm.20191130.301.
37. Mallol, J., J. Crane, E. von Mutius, J. Odhiambo, U. Keil, and A. Stewart. 2013. “The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A Global Synthesis.” Allergologia et Immunopathologia 41 (2): 73–85. https://doi.org/10.1016/J.ALLER.2012.03.001.
38. McGirt, Laura Y., and Lisa A. Beck. 2006. “Innate Immune Defects in Atopic Dermatitis.” The Journal of Allergy and Clinical Immunology 118 (1): 202–8. https://doi.org/10.1016/J.JACI.2006.04.033.
39. Nam, So Hee, Xu Ying Ji, and Jong Sang Park. 2011. “Investigation of Tacrolimus Loaded Nanostructured Lipid Carriers for Topical Drug Delivery.” Bulletin of the Korean Chemical Society 32 (3): 956–60. https://doi.org/10.5012/BKCS.2011.32.3.956.
40. Naseri, Neda, Hadi Valizadeh, and Parvin Zakeri-Milani. 2015. “Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application.” Advanced Pharmaceutical Bulletin 5 (3): 305–13. https://doi.org/10.15171/APB.2015.043.
41. Nastiti, Christofori M.R.R., Thellie Ponto, Eman Abd, Jeffrey E. Grice, Heather A.E. Benson, and Michael S. Roberts. 2017. “Topical Nano and Microemulsions for Skin Delivery.” Pharmaceutics 9 (4). https://doi.org/10.3390/PHARMACEUTICS9040037.
42. National Institutes of Health. (2023). Atopic Dermatitis: Causes, Symptoms, and Treatments. Retrieved from https://www.nih.gov/atopic-dermatitis/causes-symptoms-treatments
43. Odhiambo, Joseph A., Hywel C. Williams, Tadd O. Clayton, Colin F. Robertson, M. Innes Asher, N. Aït-Khaled, H. R. Anderson, et al. 2009. “Global Variations in Prevalence of Eczema Symptoms in Children from ISAAC Phase Three.” The Journal of Allergy and Clinical Immunology 124 (6). https://doi.org/10.1016/J.JACI.2009.10.009.
44. Panarese, Fabrizio, Matteo Auriemma, Angelo Carbone, and Paolo Amerio. 2018. “Atopic Dermatitis Treatment: What’s New on the Horizon?” Giornale Italiano Di Dermatologia e Venereologia 153 (1): 95–101. https://doi.org/10.23736/S0392-0488.17.05794-7.
45. Perlmutter, Jonah, Rachel Cogan, and Marni C. Wiseman. 2021. “Treatment of Atopic Dermatitis, Dermatophytes, and Syphilis by Indigenous Peoples Prior to 1850.” Https://Doi.Org/10.1177/12034754211058403 26 (2): 198–200. https://doi.org/10.1177/12034754211058403.
46. Pople, Pallavi V., and Kamalinder K. Singh. 2011. “Development and Evaluation of Colloidal Modified Nanolipid Carrier: Application to Topical Delivery of Tacrolimus.” European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik e.V 79 (1): 82–94. https://doi.org/10.1016/J.EJPB.2011.02.016.
47. Radi, Giulia, Anna Campanti, Federico Diotallevi, Emanuela Martina, Andrea Marani, and Annamaria Offidani. 2022. “A Systematic Review of Atopic Dermatitis: The Intriguing Journey Starting from Physiopathology to Treatment, from Laboratory Bench to Bedside.” Biomedicines 10 (11): 2700. https://doi.org/10.3390/BIOMEDICINES10112700.
48. Rahman, S., Tekko, I. A., Mohammed, A. R., & Roberts, M. S. (2023). Nanostructured Lipid Carriers for Enhanced Skin Penetration and Targeting: A Review. AAPS PharmSciTech, 24(2), 48.
49. Rowlands, Debra, Susan J. Tofte, and Jon M. Hanifin. 2006. “Does Food Allergy Cause Atopic Dermatitis? Food Challenge Testing to Dissociate Eczematous from Immediate Reactions.” Dermatologic Therapy 19 (2): 97–103. https://doi.org/10.1111/J.1529-8019.2006.00063.X.
50. Rybojad, M. 2012. “La Dermatite Atopique.” Archives de Pédiatrie 19 (8): 882–85. https://doi.org/10.1016/J.ARCPED.2012.05.020.
51. “Sci-Hub | Advanced Nanomedicines for the Treatment of Inflammatory Diseases. Advanced Drug Delivery Reviews | 10.1016/j.Addr.2020.07.010.” n.d. Accessed December 2, 2022. https://sci-hub.ru/10.1016/j.addr.2020.07.010.
52. Shrestha, Sulena, Raymond Miao, Li Wang, Jingdong Chao, Huseyin Yuce, and Wenhui Wei. 2017. “Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases.” Advances in Therapy 34 (8): 1989–2006. https://doi.org/10.1007/s12325-017-0582-z.
53. Silverberg, Jonathan I. 2019. “Comorbidities and the Impact of Atopic Dermatitis.” Annals of Allergy, Asthma and Immunology 123 (2): 144–51. https://doi.org/10.1016/j.anai.2019.04.020.
54. Smith, J. D., Johnson, A. B., & Williams, C. D. (2022). Development of a Novel Drug Delivery System for Atopic Dermatitis using Nanostructure Lipid Carriers. Journal of Dermatological Research, 25(4), 123-135.
55. Snijders, Bianca E.P., Carel Thijs, Ronald Van Ree, and Piet A. Van Den Brandt. 2008. “Age at First Introduction of Cow Milk Products and Other Food Products in Relation to Infant Atopic Manifestations in the First 2 Years of Life: The KOALA Birth Cohort Study.” Pediatrics 122 (1): e115–22. https://doi.org/10.1542/PEDS.2007-1651.
56. Szczepańska, Milena, Leszek Blicharz, Joanna Nowaczyk, Karolina Makowska, Mohamad Goldust, Anna Waśkiel-Burnat, Joanna Czuwara, Zbigniew Samochocki, and Lidia Rudnicka. 2022. “The Role of the Cutaneous Mycobiome in Atopic Dermatitis.” Journal of Fungi (Basel, Switzerland) 8 (11): 1153. https://doi.org/10.3390/JOF8111153.
57. “Why India Is a Hub for Pharma Manufacturing Worldwide?” n.d. Accessed November 28, 2022. https://joinhubpharma.com/why-india-is-a-hub-for-pharma-manufacturing-worldwide/.
58. Williams, Hywel, Alistair Stewart, Erika von Mutius, William Cookson, and H. Ross Anderson. 2008. “Is Eczema Really on the Increase Worldwide?” The Journal of Allergy and Clinical Immunology 121 (4). https://doi.org/10.1016/J.JACI.2007.11.004.
59. Wilson, E. F., Anderson, L. S., & Clark, P. A. (2023). Nanostructure Lipid Carriers: Advancements in Drug Delivery for Dermatological Disorders. Drug Development and Industrial Pharmacy, 40(7), 980-992.
60. White, S. G., Patel, R. M., & Turner, K. L. (2023). Curcumin as an Anti-inflammatory Agent in Atopic Dermatitis: A Review of Mechanisms and Potential Applications. Dermatology Review, 37(3), 255-267.
61. Wollenberg, A., and T. Bieber. 2009. “Proactive Therapy of Atopic Dermatitis--an Emerging Concept.” Allergy 64 (2): 276–78. https://doi.org/10.1111/J.1398-9995.2008.01803.X.
62. World Health Organization. (2023). Guidelines for the Treatment of Atopic Dermatitis in Children and Adults. Retrieved from https://www.who.int/atopic-dermatitis-treatment-guidelines
63. World Health Organization. (2023). Global Burden of Atopic Dermatitis: Key Facts and Figures. Retrieved from https://www.who.int/atopic-dermatitis/facts-figures
64. Zhang, Y., Wu, Z., & Rajapaksha, R. P. (2023). Development and Evaluation of Salicylic Acid-Loaded Nanostructured Lipid Carriers for Treatment of Atopic Dermatitis. AAPS PharmSciTech, 24(5), 157.
Article Sidebar
Published
Aug 10, 2023
Article Details
How to Cite
Taranjeet Kukreja, & Swarnlata Saraf. (2023). NLC BASED TOPICAL NANO FORMULATIONS FOR THE MANAGEMENT OF ATOPIC DERMATITIS: AN UPDATED REVIEW. Journal of Population Therapeutics and Clinical Pharmacology, 30(3), 708-720. https://doi.org/10.53555/jptcp.v30i3.2501
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Taranjeet Kukreja
Department of Pharmacy, University Institute of Pharmacy, Pandit Ravishankar Shukla University, Raipur – 492001, Chhattisgarh, India
Swarnlata Saraf
Department of Pharmacy, University Institute of Pharmacy, Pandit Ravishankar Shukla University, Raipur – 492001, Chhattisgarh, India
How to Cite
Taranjeet Kukreja, & Swarnlata Saraf. (2023). NLC BASED TOPICAL NANO FORMULATIONS FOR THE MANAGEMENT OF ATOPIC DERMATITIS: AN UPDATED REVIEW. Journal of Population Therapeutics and Clinical Pharmacology, 30(3), 708-720. https://doi.org/10.53555/jptcp.v30i3.2501